-
Solasia Announces Launch of Darvias® in Japan
Solasia Announces Launch of Darvias® in Japan
Share
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
Contacts
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
Tel: +81 3 5843 8046 (TOKYO)
info@solasia.co.jp
Solasia Pharma K.K.
More News From Solasia Pharma K.K.
Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan
TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”) by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd....
Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)
TOKYO--(BUSINESS WIRE)--Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate Darinaparsin...
Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan
TOKYO--(BUSINESS WIRE)--NDA filed in Japan ahead of anywhere else in the world, New anti-cancer drug with a novel mechanism of action, Orphan Drug Designation in the US & EU...
